/
EPRX
$6.59-$0.01 (-0.15%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$431.2M
65M shares
52-week range
$4.88 – $9.32
39% from low
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$3.64
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $125.4K | $207.4K | $117.1K | $112.4K | $0 | $0 | $163.5K | $331.9K |
| Gross profit | −$125.4K | −$207.4K | −$117.1K | −$112.4K | $0 | $0 | −$163.5K | −$331.9K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.8M | $3.5M | $1.1M | $7.6M | $13.6M | $15.3M | $16.1M | $29.5M |
| Operating income | −$12.0M | −$6.8M | −$2.5M | −$14.6M | −$17.6M | −$21.0M | −$27.0M | −$53.7M |
| EBITDA | −$14.5M | −$5.7M | −$2.0M | −$17.2M | −$17.9M | −$20.8M | −$25.0M | −$53.3M |
| Net income | −$13.2M | −$7.4M | −$4.0M | −$18.0M | −$18.5M | −$21.2M | −$25.5M | −$53.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.03 | -0.56 | -0.31 | -1.63 | -0.96 | -0.88 | -0.76 | -1.05 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.19 | $-1.62–$-0.58 | 6 |
| 2027 | $16M | $-1.23 | $-1.77–$-0.37 | 7 |
| 2028 | $7M | $-1.61 | $-2.91–$-0.53 | 6 |
| 2029 | $0 | $-1.66 | $-1.66–$-1.66 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.43
Price
$6.59
Implied downside
-78%
Peer comparison
Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
www.eupraxiapharma.com- Employees
- 49
- IPO / List date
- Jun 9, 2021
Held by traders on TradeandTell
No one on the platform currently holds EPRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in EPRX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EPRX yet.
